CTIS2022-500706-18-01招募中1 期
A phase I trial to assess safety and immunogenicity of an HLAII-targeted DNA vaccine against influenza H7N9
Oslo University Hospital Hf0 个研究点目标入组 30 人开始时间: 2023年2月28日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
不适用
A Phase I trial to assess safety and immunogenicity of i.d. DNA priming and i.m. MVA boosting in healthy volunteers in MozambiqueHIV/AIDSPACTR201106000304583Swedish Institute for Infectious Disease Control24
已完成
1 期
Study to evaluate safety and possible adverse reactions, especially serious, with a vaccine for measles and rubella in healthy subjects.Measles and RubellaRBR-9hckj4Bio-Manguinhos/Fiocruz/MS
Unknown
2 期
HIVIS03PACTR2009040001075080Swedish Institute for Infectious Disease Control (SMI)
已完成
不适用
TaMoVac-01PACTR2010050002122368Swedish Institute for Infectious Disease Control120
已完成
不适用
Phase I clinical trial to assess safety and immunogenicity of an MVA-based influenza H5 vaccine in healthy adultsflu10047438InfluenzaNL-OMON38408Erasmus MC, Universitair Medisch Centrum Rotterdam27